- Home
- BW vs FULC Comparison
BW vs FULC Comparison
Compare BW & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- FULC
- Stock Information
- Founded
- BW 1867
- FULC 2015
- Country
- BW United States
- FULC United States
- Employees
- BW N/A
- FULC N/A
- Industry
- BW Building Products
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- BW Industrials
- FULC Health Care
- Exchange
- BW Nasdaq
- FULC Nasdaq
- Market Cap
- BW 182.0M
- FULC 210.9M
- IPO Year
- BW N/A
- FULC 2019
- Fundamental
- Price
- BW $1.15
- FULC $3.85
- Analyst Decision
- BW Strong Buy
- FULC Hold
- Analyst Count
- BW 3
- FULC 9
- Target Price
- BW $4.50
- FULC $7.63
- AVG Volume (30 Days)
- BW 799.7K
- FULC 356.4K
- Earning Date
- BW 03-13-2025
- FULC 02-25-2025
- Dividend Yield
- BW N/A
- FULC N/A
- EPS Growth
- BW N/A
- FULC N/A
- EPS
- BW N/A
- FULC N/A
- Revenue
- BW $878,224,000.00
- FULC $80,871,000.00
- Revenue This Year
- BW N/A
- FULC $2,823.78
- Revenue Next Year
- BW N/A
- FULC N/A
- P/E Ratio
- BW N/A
- FULC N/A
- Revenue Growth
- BW N/A
- FULC 2987.86
- 52 Week Low
- BW $0.75
- FULC $2.86
- 52 Week High
- BW $2.99
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- BW 31.53
- FULC 47.75
- Support Level
- BW $1.30
- FULC $3.64
- Resistance Level
- BW $1.45
- FULC $3.94
- Average True Range (ATR)
- BW 0.09
- FULC 0.18
- MACD
- BW -0.01
- FULC 0.02
- Stochastic Oscillator
- BW 2.56
- FULC 84.21
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.